{"symbol":"REGN","fiscalQuarter":"Q1-2015","reportDate":"2015-05-07","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q1-2015","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Down 0.3%","keyNumbers":[{"metric":"EPS","actual":"$2.88","expected":"N/A","surprise":"+48.45%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted strong performance in key product areas.","They emphasized ongoing investment in research and development.","No specific guidance was provided for future quarters."],"summary":"Overall, management expressed confidence in the company's product pipeline and market position. However, they did not provide specific guidance for the upcoming quarters."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron Pharmaceuticals reported a strong earnings surprise with an EPS of $2.88, significantly above expectations. Despite this positive news, the stock fell by 0.3% in reaction, indicating that investors may have been looking for more clarity on future revenue and guidance. The lack of revenue details and guidance may have contributed to the stock's slight decline.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q1 2015 earnings: EPS beat by 48.45%. Stock down 0.3%. Full breakdown."}}